Aims: This prospective cross-sectional observational study aimed at reporting the demographics of ACS patients admitted to Assiut University Hospital, Egypt, and validating both TIMI (Thrombolysis in Myocardial Infarction) and GRACE (Global Registry of Acute Coronary Events) scores in the prediction of both in-hospital MACE and 30-day mortality and recurrent MI in both ST-elevation myocardial infarction (STEMI) and unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) patients.
Introduction
Patients presenting with acute coronary syndromes (ACS) with or without ST segment elevation despite having both common etiology and pathophysiology form a heterogeneous population with variable short and long prognoses. Early risk stratification plays an important role in deciding the optimal management of these patients, and the concept of risk assessment has become widespread in the last few years [1, 2] . Risk stratification in ACS aims to identify patients at high risk of death or recurrent ischemic events who might benefit from further investigations and treatment. Moreover, it can identify low-risk patients amenable to early hospital discharge. Thus, risk stratification allows better cost-benefit clinical resource utilization, such as decisions regarding transfer to tertiary centers, level of care, length of hospital stay, and which pharmacological and interventional treatments should be used [2] .
Several prognostic scores have recently been proposed. Some are derived from clinical trials such as TIMI (Thrombolysis in Myocardial Infarction) [3, 4] , PURSUIT (Platelet glycoprotein IIb-IIIa in Unstable angina, Receptor Suppression using Integrilin Therapy trial) [5] , and GUSTO (Global Utilization of Streptokinase and t-PA for Occluded coronary arteries) [6] scores. Others are derived from registries and cohort studies such as PREDICT (the Predicting Risk Of Death In Cardiac Disease Tool) [7] , CCP (Cooperative Cardiovascular Project) [8] and GRACE (Global Registry of Acute Coronary Events) [9] scores. Both TIMI and GRACE scores can be calculated from initial clinical history and electrocardiographic and laboratory data collected on admission. Both scores are sufficiently simple to be practical at the bedside for risk assessments across a wide spectrum of patients with ACS [1, 2] .
Subjective risk judgments by treating physicians have been reported to affect the selection of more aggressive therapies than would be chosen if patients were objectively stratified by validated risk score models. Risk scores still confer independent and greater prognostic information compared with physician risk assessment after adjusting for treatment differences. Therefore, dedicated efforts to improve and implement risk stratification may enhance the overall care process and resource utilization [10] .
Risk stratification scoring systems do predict outcome more accurately in the original setting than when used for other patient populations. This difference has been attributed to the significant differences with regard to the initial patient population on which the score design was based [11] . Several studies have assessed ACS risk stratification scores in a number of countries [4, 9, 10, [12] [13] [14] . In addition, the comparative performance of these scores in representative patient populations has not been well studied [11] . In addition, data are lacking concerning the demographics and clinical presentation patterns of ACS in Egypt.
This study aimed to report the demographics of ACS patients admitted to Assiut University Hospital, comparing ST segment elevation myocardial infarction (STEMI) with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) patients. In addition, the study aimed to validate both TIMI and GRACE scores as prognostic tools to predict both in-hospital major acute cardiac events (MACE) and 30-day all-cause mortality and recurrent MI in both STEMI and UA/NSTEMI patients.
Methods
This study was a prospective cross-sectional observational study that included all patients >18 years old who had ACS and were admitted to the coronary care unit in Assiut University Hospital over a period of one year: from the 1st of April 2011 to the 31st of March 2012. All patients provided a written informed consent. The study was approved by our faculty ethics committee and was adherent to the regulations of the Declaration of Helsinki.
Ischemic type chest pain was identified as being retrosternal, severe, crushing, squeezing, constricting, or discomforting with frequent radiation to the left arm or known history of coronary artery disease, including MI [2] . Patients were assigned to the categories of STEMI, NSTEMI, or unstable angina, according to standard definitions [2, 15] .
The exclusion criteria were (1) patients with non-coronary causes of chest pain (i.e., trauma, aortic aneurysm, pulmonary embolism, or pericarditis), (2) patients with acute dyspnea from non-cardiac causes, and (3) significant co-morbidity reducing life expectancy to <1 year as patients with advanced liver diseases, cerebrovascular diseases, malignancy and chronic lung diseases that could affect patient prognosis.
Data collection
Patients were managed according to the European guidelines for the management of ACS patients [1, 16] . STEMI patients were reperfused using streptokinase. Coronary intervention was performed when it was financially eligible. The daily review of admitted cases with ACS fulfilling the inclusion criteria was performed. The full history and examination data were reported. A standard 12-lead electrocardiogram (ECG) record was recorded at a paper speed of 25 mm/s and amplification of 10 mm/mV. Laboratory evaluation at the baseline included random blood sugar, serum lipid profile, serum urea and creatinine, creatine kinase, troponin and hemoglobin level on admission. Daily follow-up evaluation of serum urea, creatinine, and creatine kinase throughout the admission period was also performed.
Risk score assessment
The GRACE score was calculated as previously reported [2, 9] from the following variables and weighted according to risk model: age, history of congestive heart failure, history of MI, heart rate, systolic blood pressure on presentation, ST-segment deviation, initial serum creatinine and cardiac enzymes raised above the upper limit of normal for that laboratory.
For STEMI, the TIMI risk score [4] is a weighted integer score based on eight clinical risk indicators that can be easily ascertained at presentation. For each patient, the score was calculated as the arithmetic sum of the points of each risk feature present (range from 0 to 14).
For NSTEMI, the TIMI score [3] is based on clinical indicators, each assigned one point, ranging from 0 to 7.
In-hospital outcomes
All of the patients were reviewed daily until hospital discharge to record major acute cardiac events (MACE). Only the most serious events of major adverse cardiac events were used to calculate the cumulative major adverse cardiac events per patient according to the following sequence: death > asystole > cardiogenic shock > pulmonary edema > serious arrhythmia > recurrent non-fatal MI > recurrent or refractory angina. MACE is reported according to the standard definitions [2, 15] .
The patients were followed up for 30 days from admission by telephone interviews after being discharged. The primary endpoints at follow-up were all-cause mortality and recurrent non-fatal MI [2, 15] .
Statistical analysis
Risk scores were calculated according to TIMI and GRACE risk score models [3, 4, 9] . Data were analyzed using Statistical Package for Social Sciences (SPSS) version 16.0. The 0.05 level was used as the cut-off value for statistical significance. The count and percentage were used for describing and summarizing qualitative data. The arithmetic mean and standard deviation (SD) were used as measures of central tendency and dispersion, respectively, for quantitative data. The differences in mortality rates for increasing TIMI and Grace Risk scores values were assessed using the v 2 test for trend. The risk score discrimination models that distinguish well between patients who die and those who survive are said to have good discrimination. The discrimination of TIMI and Grace scores were tested using Receiver Operating Characteristics (ROC) curve (c-statistics). The c-index ranges from 0 to 1, with higher values indicating better discrimination. The ROC curve was constructed using 10% stepwise increments in predicted mortality. The curve is generated by plotting the true positive proportion or sensitivity (Y axis) against the false positive proportion, which is 1-specificity (X axis), across the range of model to produce the curve. A model with equal probability of producing the correct or incorrect result (e.g., flipping a coin) produces a straight line at a 45°angle with is half of the area under the curve. Models with better discrimination incorporate larger areas under the curve to a theoretical maximum of 1.0. Comparison of ROC curves to test the statistical significance of the difference between the areas under the dependent ROC curves (derived from the same cases) was performed with the method of DeLong et al. [17] using MedCalc Statistical software Version 13.1.2 (Ostend, Belgium).
Results

Studied sample and follow-up
The total number of patients included in the study was 795. The patients were divided into two groups: 270 patients (34%) with STEMI and 525 patients (66%) with UA/NSTE-MI. The number of UA patients was 330 (41.5%), and the number of NSTEMI patients was 195 (24.5%). Sixty patients (7.5%) were lost to follow-up: 12 patients died in-hospital, and 48 patients were lost to follow-up.
Distribution of the sample according to socio-demographic variables and history and GRACE variables (Table 1)
Both the STEMI and UA/NSTEMI groups had a similar age distribution with a mean age of 58 ± 11 years and 57 ± 12 years, respectively. The highest percentage of patients was in the age group less than 65 years, being 70% for both groups, and the lowest percentage of patients was in the age group P74 years, being 7% for the STEMI group and 6% for the UA/NSTEMI group. The STEMI group had a significantly higher rate of male gender (72% versus 64%), smoking (51% versus 38%), diabetes (45% versus 34%), dyslipidemia (39% versus 29%) and family history of CAD (16% versus 7%). Interestingly, the percentage of patients who had a previous history of ischemia in the UA/NSTEMI group was 70%. This was in the form of STEMI in 26% of patients and UA/ NSTEMI in 44% of patients, compared with only 24% patients with a history in the STEMI group in the form of STEMI for 13% of patients and UA/NSTEMI in 11% of patients (p < 0.001). The UA/NSTEMI group had a higher rate of hypertension (59% versus 33%), diabetes (45% versus 34%), previous coronary angiography (31% vs 9%), and previous coronary artery bypass grafting (3% vs 0). Patients with UA/NSTEMI had a longer duration since the first angina pain until presentation (96 ± 152 h) compared with STEMI patients (20 ± 32 h; p < 0.0001). On the other hand, STEMI patients had more warning rest angina pain in the preceding 24 h (5 ± 2) compared with UA/NSTEMI patients (3 ± 2; p < 0.0001).
Regarding heart rate, both groups had the highest percentage of patients in the heart rate group 60-100 bpm (82.2% and 87.4%, respectively). The major portion of the two groups had a systolic blood pressure P140 mmHg, which was 48.9% in the STEMI group and 42.9% in the UA/NSTEMI group. The percentage of patients with elevated creatinine was almost equal in both groups, being 21.3% in patients with UA/NSTE-MI versus 21.5% in STEMI patients. The incidence of developing heart failure was greater in the STEMI group than in Validation of TIMI and GRACE scores in ACS patients the UA/NSTEMI group, 15.6% and 10.9%, respectively. Cardiac arrest on admission was significantly higher for the STEMI (36 patients, 13.3%) compared with the UA/NSTEMI (12 patients, 2.3%). Similarly, cardiogenic shock upon admission was significantly higher with STEMI (12 patients, 4.4%) compared with UA/NSTEMI (three patients, 0.6%). On the other hand, pulmonary edema at the presentation had a trend to be higher with UA/NSTEMI (42 patient, 8.0%) compared with STEMI (15, 5.6%). However, the difference did not reach statistical significance. Troponin I was positive in 95.8% of STEMI patients on admission, whereas it was positive in 50.2% of UA/NSTEMI patients. The number of patients who underwent coronary angiography during their hospital stay was very low in both groups (1% in STEMI and 5% in UA/NSTEMI, p < 0.01).
Distribution of TIMI score factors among patients with STEMI (Table 2)
There were 21.2% of patients in the STEMI group who had either diabetes mellitus or hypertension or angina. On the other hand, a small percentage of patients had a systolic blood pressure <100 mmHg (11.1%) and heart rate >100 bpm (30%). Only 15.6% of STEMI patients were complicated by (Table 3) In-hospital MACE was significantly higher among the STEMI patients (23.3%) compared with the UA/NSTEMI (13.7%).
There was a significantly higher mortality, asystole, cardiogenic shock, serious arrhythmia, recurrent non-fatal MI with STEMI, whereas pulmonary edema displayed a trend toward being higher in the UA/NSTEMI group (P value did not reach significance). The GRACE score performance in predicting in-hospital MACE was significantly better compared with TIMI score in both the STEMI (AUC 0.89 ± 0.03 versus 0.74 ± 0.04, respectively, p 0.0001, Fig. 1A) and UA/NSTEMI patients (AUC 0.90 ± 0.02 versus 0.72 ± 0.03, respectively, p < 0.0001, Fig. 1D ).
Overall 30-day follow-up results
The overall 30-day follow-up results of patients surviving the in-hospital course displayed a significantly higher incidence of mortality in the STEMI group (21/243, 9%) compared with the UA/NSTEMI group (9/492, 2%; p < 0.0001). Recurrent non-fatal MI was also significantly higher in the STEMI group (84/243, 35%) compared with the UA/NSTEMI group (75/492, 15%; p < 0.0001).
The mean TIMI score was significantly higher in patients who died during the 30-day follow up, in both the STEMI group (5.9 ± 1.8) and the UA/NSTEMI group (5.0 ± 0.1) compared with surviving patients (3.1 ± 1.8 and 3.5 ± 1.1, respectively, p < 0.0001 for both). Similarly, the mean GRACE score was significantly higher in patients who died during the 30-day follow-up, in both the STEMI group (333 ± 47) and the UA/NSTEMI group (284 ± 28) compared with surviving patients (215 ± 29 and 171 ± 16, respectively, p < 0.0001 for both). As shown in Fig. 2 , it was found that there is a pattern of an increasing percentage in the observed 30-day mortality rate with increased risk score category for both the TIMI and GRACE scores in both the STEMI and UA/NSTEMI groups. The differences in mortality rates for increasing TIMI and GRACE risk score values were assessed using the v 2 test for trends. The p for the trend value for the GRACE score was <0.001. The p for trend value for the TIMI score was significant (<0.001). In STEMI patients, both the GRACE and TIMI scores performed comparably well in predicting both mortality (AUC 0.83 ± 0.06 and 0.86 ± 0.03, respectively, p 0.5, Fig. 1 (B) and recurrent non-fatal MI (AUC 0.73 ± 0.04 and 0.72 ± 0.03, respectively, p 0.7, Fig. 1 (C) , whereas in patients with UA/NSTEMI, the GRACE score performed significantly better in predicting both mortality with an AUC of 0.97 ± 0.01 compared with 0.89 ± 0.02 for TIMI score (p < 0.0001; Fig. 1 (E) and recurrent non-fatal MI with an AUC of 0.85 ± 0.03 compared with 0.75 ± 0.03 for TIMI score (p 0.0001; Fig. 1 (D) .
Discussion
Patient demographics and baseline characteristics
The distribution of ACS patients admitted to our hospital was 34% for STEMI, 24.5% for NSTEMI, and 41.5% for unstable angina. This distribution is similar to the GRACE registry data with 32% STEMI, 27% NSTEMI, and 41% UA [18] and the French registry of ACS (ONACI) with 31% STEMI, 29% NSTEMI, and 40% UA [19] . Male patients constituted more than half of our studied sample (66.8%). This was similar to most of the recent studies supporting that male gender increases the risk of developing ACS [9, 10, 18, 19] . Our ACS patients are relatively young with a mean age of approximately 57 years compared with the Western data with a mean age of approximately 66 years [9, 10, 18, 19] . There were no significant differences in the baseline clinical characteristics, including the prevalence of diabetes mellitus, hypertension, dyslipidemia, angina, systolic blood pressure, and aspirin use in the previous week and initial serum creatinine between the studied sample in our study and those found in other recent studies [9, 10, 18, 19] .
ST-segment deviation at presentation was reported in 62.9% of UA/NSTEMI patients. The reported rates of ST deviation at presentation varied much in the different reports being 55.9% [11] , 45-47% [20] , 32-43% [12] , 33.7% [21] , and 26% [10] . There was also a significant difference in the positive cardiac marker percentage at presentation, which was much greater in our study, reaching 69.5% (95.8% in STEMI, 50.2% in UA/NSTEMI), than other studies (30-35%) [9, 10, 12, 21] . This may be due to the delay in patients' referral to hospitals, as 73.3% of the STEMI patients reached the hospitals after more than 4 h from the pain onset, which will give more time to troponin to be detected in the blood. The resuscitated cardiac arrest on admission was reported to be 1.2% [9] to 1.5% [21] in all ACS patients compared with 6% in our study (13.3% in STEMI and 2.3% in UA/NSTE-MI). This difference may also be due to delayed presentation. The Killip class distribution of our patients at the time of presentation was comparable to the published data [12, 21] .
During the calculation of TIMI score of UA/NSTEMI for patients without prior coronary angiography, we assigned 1 point to that score item if there was a history of myocardial infarction or coronary revascularization either by PCI or CABG, in accordance with the suggestion by the authors of TIMI RS [22] . In patients with UA/NSTEMI, 30.9% were assigned to have coronary artery stenosis P50% according to the mentioned recommendation. Our results were different from those of Maureen Chase et al. [23] , where 18% of the 
In-hospital outcomes
In this study, STEMI was associated with a higher incidence of in-hospital MACE, in-hospital mortality, recurrent non-fatal MI, recovered asystole, cardiogenic shock, and serious arrhythmia but less incidence of pulmonary edema during the in-hospital course compared with UA/NSTEMI patients. At the 30-day follow-up, the STEMI group still had a higher incidence of all-cause mortality and recurrent non-fatal MI. These findings are consistent with those of the GRACE study [24] and ONACI registry, which reported higher in-hospital complications and higher mortality in the first 24 h in STEMI patients [19] .
In-hospital mortality displayed considerable variation in different series depending on the sample size, population stud-ied, representation of each ACS entity (UA, NSTEMI, and STEMI) and also the number of patients who underwent PCI during the hospital stay, revascularization rate, and technique. Some studies, such as Granger et al. [21] , excluded mortality cases in the first 24 h from some sites, which represented 22% of the total in-hospital mortality cases. Other studies excluded patients with a prolonged hospital stay of more than 90 days [12] .
We reported an in-hospital mortality of 4.4% in STEMI patients and no in-hospital mortality in UA/NSTEMI patients. A study conducted across Europe in 2000 reported an in-hospital mortality of 5.9% among patients with acute MI, 4.3% in patients with MI evolving from UA and 1.6% in patients with UA [25] . On the other hand, Morrow et al. found an in-hospital mortality of 12.6% in STEMI patients. Bradshaw et al. [13] found that the crude in-hospital mortality among the whole ACS spectrum was 11.0% overall, being 8.9%, 11.1% and 11.5% at small, community and teaching hospitals, respectively. Patients with STEMI constituted 49.5% of their patients. Of these patients, 59% were treated with reperfusion therapy, mostly thrombolysis [12] . Granger et al. reported in-hospital mortality of 4.6% for the whole ACS sample [21] . Yan et al., concerning patients with NSTE-ACS, found an in-hospital mortality of 1.8% [10] .
Thirty-day outcomes
We found that patients with STEMI had a higher all-cause mortality rate (9%) and recurrent non-fatal MI (35%) at 30 days compared with UA/NSTEMI patients (2% and 15%, respectively). Morrow et al., in a large validation study of TIMI score recruiting 84,029 patients with STEMI, reported a 30-day mortality of 5.7% [4] . A small single-center retrospective study of 460 consecutive patients reported a 30day all-cause mortality rate of 2.8% and a recurrent non-fatal MI rate of 5.2% [11] .
STEMI was associated with a higher risk of short-term mortality compared with UA and NSTEMI in the ONACI registry [19] . Sangu et al. reported that STEMI was an independent predictor of re-hospitalization within 30 days after an ACS [20] . In addition, data from the United Kingdom indicated that the presence of MI was associated with a higher 30-day mortality rate being 4.5%, 10.4%, and 12.9% in the UA, NSTEMI, and STEMI groups, respectively [26] .
Evaluation of the risk score models
The GRACE risk score was originally designed to predict all-cause mortality, and the TIMI risk score was designed to predict the composite endpoint of death and myocardial re-infarction. In the current study, both scores were valid in our patient population and successfully predicted in-hospital MACE, 30-day all-cause mortality, and 30-day recurrent non-fatal MI with a good discriminative ability (c-statistics 0.72-0.97) in both STEMI and UA/NSTEMI patients. The GRACE score displayed a better discriminative ability than TIMI score in all of these occasions except in STEMI patients. Both scores performed comparably in predictions of 30-day mortality and recurrent non-fatal MI.
The discriminative ability of both scores was validated in numerous reports in different populations [9, 10, [12] [13] [14] . The Figure 2 Percentages of observed 30-day mortality (A) by TIMI score categories among the STEMI group, (B) by TIMI score categories among the UA/NSTEMI group, and (C) by GRACE score categories among the total studied sample. superiority of the GRACE score was demonstrated in a recently published large meta-analysis that included all ACS types [27] . In a study from Portugal on patients with UA/NSTEMI, GRACE performed better than TIMI score in predicting oneyear composite mortality and recurrent MI, whereas at 30 days the difference was of borderline significance [11] . Another small study from Portugal reported the superiority of the GRACE score in predicting in-hospital events in ACS patients [28] . Another series from the United States reported that the GRACE score provided superior discrimination compared with the TIMI score in predicting in-hospital and 6-month mortality in UA/NSTEMI patients, whereas both scores performed equally well in STEMI patients [29] . Data from a Canadian registry of UA/NSTEMI patients indicated that GRACE had a better discriminative ability in predicting both in-hospital and one-year mortalities [10] . To our knowledge, only one study has been performed in Egypt to compare both scores [14] . They found in 606 patients recruited from three hospitals in Alexandria that GRACE has a better discriminative ability than TIMI score for the prediction of mortality both in-hospital (in UA/ NSTEMI) and at six months (in both STEMI and UA/NSTE-MI patients).
A possible explanation for this superiority of GRACE is that it was developed from a community-based cohort, whereas TIMI score was developed from data collected from clinical trials. There are some characteristics in each trial that can make the population within the trials different from others and from the community, which may not be adequately measured. This can result in the trial-based population result not being entirely generalizable to the community [30] . Granger et al. summarized the advantages of the GRACE model over TIMI score in terms of three main differences. First, it is the first mortality model to span the entire spectrum of ACS. This advantage is important because ACS patients are not only difficult to categorize at the time of presentation as having MI or unstable angina but also may have varying amounts of dynamic ST-segment shift and may rapidly progress from one category to another. Second, it is based on a relatively unselected patient population, representing those observed in general practice (community based). Third, it incorporates new variables that add considerable predictive information, such as serum creatinine [21] .
The advantage of TIMI risk score is that it is based on clinical information, rendering it suitable for bedside early risk stratification with no need for a computer. Patients with ACS are in unstable condition, necessitating continuous risk stratification throughout the entire hospital admission period, which makes TIMI score more feasible for use by physicians [13] .
Study limitations: Details on management data could not be collected and hence analysis of the effect of management strategy on the outcome was not done. This is considered a limitation of this study.
Conclusion
ACS occurs at a relatively young age in our locality, in patients sharing the common known risk factors of CAD. STEMI patients, in our locality, represent approximately one-third of ACS patients and are associated with worse in-hospital as well as 30-day outcomes. Both TIMI and GRACE risk scores are valid for use for ACS patients in the Assiut governorate, with a better discriminative ability for the GRACE score, especially in UA/STEMI patients.
